Дифференциальная диагностика локальной формы гранулематоза с полиангиитом: поражение органа зрения и органа слуха (часть 2)
https://doi.org/10.14412/1996-7012-2023-2-7-15
Аннотация
Гранулематоз с полиангиитом (ГПА) – первичный васкулит, ассоциированный с антинейтрофильными цитоплазматическими антителами, характеризующийся некротизирующим васкулитом с преимущественным вовлечением мелких сосудов различной локализации и некротизирующим гранулематозным воспалением с многогранными клиническими проявлениями. ГПА остается одним из самых тяжелых и прогностически неблагоприятных системных васкулитов. Во второй части статьи представлены данные о дифференциальной диагностике дебюта заболевания с поражения органа зрения и органа слуха, которая требует междисциплинарного подхода и взаимодействия между врачами разных специальностей. При рефрактерном течении локальной формы ГПА целесообразна иммуносупрессивная терапия, включающая глюкокортикоиды и ритуксимаб или циклофосфамид.
Ключевые слова
гранулематоз с полиангиитом,
локальная форма,
орган зрения,
орган слуха,
дифференциальная диагностика,
лечение
Об авторах
О. Н. Егорова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
Ольга Николаевна Егорова
115522, Москва, Каширское шоссе, 34А
Е. Н. Харламова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Г. М. Тарасова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия
115522, Москва, Каширское шоссе, 34А
Литература
1. Исмаилова ДС, Новиков ПИ, Груша ЯО, и др. Частота офтальмологических проявлений гранулематоза с полиангиитом (Вегенера) и их связь с системной патологией. Терапевтический архив. 2017; 89(5):69-73.
2. Ismailova DS, Abramova JV, Novikov PI, Grusha YO. Clinical features of different orbital manifestations of granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol. 2018 Sep;256(9):1751-6. doi: 10.1007/s00417-018-4014-9.
3. Holle JU, Voigt C, Both M, et al. Orbital masses in granulomatosis with polyangiitis are associated with a refractory course and a high burden of local damage. Rheumatology (Oxford). 2013 May;52(5):875-82. doi: 10.1093/rheumatology/kes382.
4. Груша ЯО, Исмаилова ДС, Абрамова ЮВ. Офтальмологические проявления гранулематоза с полиангиитом (гранулематоз Вегенера). Терапевтический архив. 2015; 87(12):111-6. doi: 10.17116/terarkh201 58712111-116.
5. Watkins AS, Kempen JH, Choi D, et al. Ocular disease in patients with ANCA-positive vasculitis. J Ocul Biol Dis Infor. 2009 Dec 12; 3(1):12-9. doi: 10.1007/s12177-009-9044-4.
6. Rothschild PR, Pagnoux C, Seror R, et al. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Semin Arthritis Rheum. 2013 Apr;42(5):507-14. doi: 10.1016/j.semarthrit.2012.08.003.
7. Tan LT, Davagnanam I, Isa H, et al. Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of systemic involvement. Ophthalmology. 2014 Jun;121(6):1304-9. doi: 10.1016/j.ophtha. 2013.12.003.
8. Jiang B, Zhao YY, Wei SH. Granulomatosis with polyangiitis: the relationship between ocular and nasal disease. Ocul Immunol Inflamm. 2013 Apr;21(2):115-8. doi: 10.3109/09273948.2012.747618.
9. Soheilian M, Bagheri A, Aletaha M. Dacryoadenitis as the earliest presenting manifestation of systemic Wegener's granulomatosis. Eur J Ophthalmol. 2002 May-Jun;12(3):241-3. doi: 10.1177/112067210201200313.
10. Talar-Williams C, Sneller MC, Langford CA, et al. Orbital socket contracture: a complication of inflammatory orbital disease in patients with Wegener's granulomatosis. Br J Ophthalmol. 2005 Apr;89(4):493-7. doi: 10.1136/bjo.2004.050039.
11. Isa H, Lightman S, Luthert PJ, et al. Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA). Int J Clin Exp Pathol. 2012;5(7):684-9. Epub 2012 Sep 5.
12. Lopes Cacola, Morais SA, Carvalho R, Moco R. Bilateral dacryoadenitis as initial presentation of a locally aggressive and unresponsive limited form of orbital granulomatosis with polyangiitis. BMJ Case Rep. 2016 May 11;2016:bcr2015214099. doi: 10.1136/bcr2015-214099.
13. Lutalo PM, D'Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). J Autoimmun. 2014 Feb-Mar;48-9:94-8. doi: 10.1016/j.jaut.2014.01.028. Epub 2014 Jan 29.
14. Kalina PH, Lie JT, Campbell RJ, Garrity JA. Diagnostic value and limitations of orbital biopsy in Wegener's granulomatosis. Ophthalmology. 1992 Jan;99(1):120-4. doi: 10.1016/s0161-6420(92)32028-7.
15. Anderson G, Coles ET, Crane M, et al. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med. 1992 Jun;83(302):427-38.
16. Marino M, Ionni I, Lanzolla G, et al. Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest. 2020 Apr; 43(4):401-11. doi: 10.1007/s40618-01901141-3.
17. Rubin PA, Foster CS. Etiology and management of idiopathic orbital inflammation. Am J Ophthalmol. 2004 Dec;138(6):1041-3. doi: 10.1016/j.ajo.2004.09.032.
18. Salah S, Abad S, Monnet D, Brezin AP. Sarcoidosis. J Fr Ophtalmol. 2018 Dec;41(10): e451-e467. doi: 10.1016/j.jfo.2018.10.002.
19. Rothova A. Ocular involvement in sarcoidosis. Br J Ophthalmol. 2000 Jan;84(1):110-6. doi: 10.1136/bjo.84.1.110.
20. Васильев ВИ, Сокол ЕВ, Седышев СХ и др. Дифференциальная диагностика ревматических и онкогематологических заболеваний, поражающих полость и придаточные пазухи носа. Терапевтический архив. 2014;86(5):62-72.
21. Thomas KW, Hunninghake GW. Sarcoidosis. JAMA. 2003 Jun 25;289(24):3300-3. doi: 10.1001/jama.289.24.3300.
22. Lynch JP 3rd. Neurosarcoidosis: how good are the diagnostic tests? J Neuroophthalmol. 2003 Sep;23(3):187-9. doi: 10.1097/00041327-200309000-00001.
23. White ES, Lynch JP 3rd. Sarcoidosis involving multiple systems : diagnostic and therapeutic challenges. Chest. 2001 May;119(5): 1593-7. doi: 10.1378/chest.119.5.1593.
24. Hu X, Zou L, Wang S, et al. Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis. Biomolecules. 2022 Sep 30;12(10):1400. doi: 10.3390/biom12101400.
25. Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012 Oct;64(10):3061-7. doi: 10.1002/art.34593.
26. Derzko-Dzulynsky L. IgG4-related disease in the eye and ocular adnexa. Curr Opin Ophthalmol. 2017 Nov;28(6):617-22. doi: 10.1097/ICU.0000000000000427.
27. Cheuk W, Yuen HK, Chan JK. Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related Sclerosing disease? Am J Surg Pathol. 2007 Apr;31(4):643-5. doi: 10.1097/01.pas.0000213445.08902.11.
28. Sato Y, Ohshima K, Ichimura K, et al. Ocular adnexal IgG4-related disease has uniform clinicopathology. Pathol Int. 2008 Aug; 58(8):465-70. doi: 10.1111/j.1440-1827.2008.02257.x.
29. Kubota T, Moritani S, Katayama M, Terasaki H. Ocular adnexal IgG4-related lymphoplasmacytic infiltrative disorder. Arch Ophthalmol. 2010 May;128(5):577-84. doi: 10.1001/archophthalmol.2010.45.
30. Plaza JA, Garrity JA, Dogan A, et al. Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease.Arch Ophthalmol. 2011 Apr;129(4):421-8. doi: 10.1001/archophthalmol.2011.16.
31. Michailidou D, Schwartz DM, Mustelin T, Hughes GC. Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy. Front Immunol. 2021 Jul 7;12:693192. doi: 10.3389/fimmu.2021.693192.
32. Wallace ZS, Naden RP, Chari S, et al. American College of Rheumatology/European League Against Rheumatism IgG4-Related Disease Classification Criteria Working Group. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2020 Jan;72(1): 7-19. doi: 10.1002/art.41120.
33. Bartalena L, Tanda ML. Current concepts regarding Graves' orbitopathy. J Intern Med. 2022 Nov;292(5):692-716. doi: 10.1111/joim.13524.
34. Bartalena L, Baldeschi L, Boboridis K, et al; European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016 Mar;5(1):9-26. doi: 10.1159/000443828.
35. Leo M, Menconi F, Rocchi R, et al. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center. Thyroid. 2015 Mar;25(3):347-51. doi: 10.1089/thy.2014.0475.
36. Marcocci C, Bartalena L, Bogazzi F, et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh). 1989 Apr;120(4):473-8. doi: 10.1530/acta.0.1200473.
37. Haroche J, Gueniche Y, Galanaud D, et al. Erdheim-Chester disease: look it in the eye. An orbital magnetic resonance imaging study. Haematologica. 2022 Nov 1;107(11): 2667-74. doi: 10.3324/haematol.2021.280510.
38. Drier A, Haroche J, Savatovsky J, et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology. 2010 May;255(2): 586-94. doi: 10.1148/radiol.10090320.
39. Broccoli A, Stefoni V, Faccioli L, et al. Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 2012 Jul; 32(7):2209-13. doi: 10.1007/s00296-0111998-4.
40. Ozkaya N, Rosenblum MK, Durham BH, et al. The histopathology of Erdheim-Chester disease: a comprehensive review of a molecularly characterized cohort. Mod Pathol. 2018 Apr;31(4):581-97. doi: 10.1038/modpathol.2017.160.
41. Крылов АС, Долгушин МБ, Рыжков АД и др. Болезнь Эрдгейма–Честера. Обзор литературы и клинический случай. Онкогематология 2020;15(2):61–75.
42. Ambrosini V, Savelli F, Merli E, et al. F-18 FDG PET/CT detects muscle involvement in Erdheim-Chester disease. Clin Nucl Med. 2012 Feb;37(2):196-7. doi: 10.1097/RLU.0b013e31823e9d54.
43. Sabino D, do Vale RHB, Duarte PS, et al. Complementary findings on 18F-FDG PET/CT and 18F-NaF PET/CT in a patient with Erdheim-Chester disease. Radiol Bras. 2017 May-Jun;50(3):202-3. doi: 10.1590/0100-3984.2015.0172.
44. Dion E, Graef C, Miquel A, et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology. 2006 Feb;238(2):632-9. doi: 10.1148/radiol.2382041525.
45. Kraniotis P, Daoussis D. Periaortitis, hairy kidneys and bone lesions. Rheumatology (Oxford). 2016 Dec;55(12):2118. doi: 10.1093/rheumatology/kew331.
46. Serratrice J, Granel B, De Roux C, et al. "Coated aorta": a new sign of Erdheim-Chester disease. J Rheumatol. 2000 Jun;27(6): 1550-3.
47. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019 Dec;19(12):e405-e421. doi: 10.1016/S1473-3099(19)30312-3.
48. Betzler ВК, Gunasekeran DV, Kempen J, et al. The Historical Evolution of Ocular Tuberculosis: Past, Present, and Future Ocul Immunol Inflamm 2022 Apr 3;30(3):593-599. doi: 10.1080/09273948.2021.1992446.
49. Uehara F, Ohba N. Diagnostic imaging in patients with orbital cellulitis and inflammatory pseudotumor. Int Ophthalmol Clin. 2002 Winter;42(1):133-42. doi: 10.1097/00004397200201000-00017.
50. Montone KT. Infectious diseases of the head and neck: a review. Am J Clin Pathol. 2007 Jul;128(1):35-67. doi: 10.1309/6BBT12WGNK77N4EH.
51. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008 Aug 15;47(4):503-9. doi: 10.1086/590004.
52. Сокол ЕВ, Торгашина АВ, Чальцев БД и др. Заболевания, протекающие с увеличением больших слюнных желез, поражением органов орбит, носа и придаточных пазух в практике ревматолога. Современная ревматология. 2021;15(6):33-40. doi: 10.14412/1996-7012-2021-6-33-40.
53. Хижняк ТВ, Астахов ЮС, Рахманова АГ. Структура заболеваний глаза в зависимости от стадии ВИЧ-инфекции. Офтальмологические ведомости. 2009;(2):15-9.
54. Butler NJ, Thorne JE.Current status of HIV infection and ocular disease. Curr Opin Ophthalmol. 2012 Nov;23(6):517-22. doi: 10.1097/ICU.0b013e328358ba85.
55. Olsen TG, Heegaard S. Orbital lymphoma. Surv Ophthalmol. 2019 Jan-Feb;64(1):45-66. doi: 10.1016/j.survophthal.2018.08.002.
56. Kisser U, Heichel J, Glien A. Rare Disea ses of the Orbit. Laryngorhinootologie. 2021 Apr;100(S 01):S1-S79. doi: 10.1055/a1384-4641.
57. Yesiltas YS, Gündüz AK. Idiopathic Orbital Inflammation: Review of Literature and New Advances. Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):71-80. doi: 10.4103/meajo.MEAJO_44_18.
58. Patnana M, Sevrukov AB, Elsayes KM, et al. Inflammatory pseudotumor: the great mimicker. AJR Am J Roentgenol. 2012 Mar; 198(3):W217-27. doi: 10.2214/AJR.11.7288.
59. Ding ZX, Lip G, Chong V. Idiopathic orbital pseudotumour. Clin Radiol. 2011 Sep; 66(9):886-92. doi: 10.1016/j.crad.2011.03.018.
60. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003 Apr;121(4):491-9. doi: 10.1001/archopht.121.4.491.
61. Mombaerts I, Bilyk JR, Rose GE, et al; Expert Panel of the Orbital Society. Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach. JAMA Ophthalmol. 2017 Jul 1;135(7): 769-76. doi: 10.1001/jamaophthalmol.2017.1581.
62. Harabuchi Y, Kishibe K, Tateyama K, et al. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society. Auris Nasus Larynx. 2021 Feb;48(1): 2-14. doi: 10.1016/j.anl.2020.07.00.
63. Robson JC, Grayson PC, Ponte C, et al; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2022 Mar;74(3):393-9. doi: 10.1002/art.41986.
64. Goderis J, de Schepper S, Vannieuwenhuyze P, Schmelzer B. Wegener granulomatosis as possible cause of vertigo: case report and review. B-ENT. 2015;11(1):67-72.
65. Yoshida N, Iino Y. Pathogenesis and diagnosis of otitis media with ANCA-associated vasculitis. Allergol Int. 2014;63(4):523–32. doi: 10.2332/allergolint.14-RAI-0774.
66. Mur T, Ghraib M, Khurana JS, Roehm PC. Granulomatosis with polyangiitis presenting with bilateral hearing loss and facial paresis. OTO Open. 2019 Jan 25;3(1):2473974X 18818791. doi: 10.1177/2473974X18818791.e Collection 2019 Jan-Mar.
67. MacDonald AS, Santa Maria PL. Wegener’s granulomatosis presenting with bilateral facial nerve palsy and limited to the head and neck. Journal of Case Reports in Medicine. 2013;1(2):1-4. doi:10.4303/jcrm/235697
68. Voudouris C, Psarommatis I, Nikas I, et al. Pediatric masked mastoiditis associated with multiple intracranial complications. Case Rep Otolaryngol. 2015;2015:897239. doi: 10.1155/2015C.
69. Devaney KO, Travis WD, Hoffman G, et al. Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol. 1990 Jun;14(6):555-64. doi: 10.1097/00000478-199006000-00006.
70. Kukushev G, Kalinova D, Sheytanov I, Rashkov R. Two clinical cases of granulomatosis with polyangiitis with isolated otitis media and mastoiditis. Reumatologia. 2017;55(5): 256-60. doi: 10.5114/reum.2017.71643. Epub 2017 Oct 28.
71. Knopf A, Chaker A, Stark T, et al. Clinical aspects of granulomatosis with polyangiitis affecting the head and neck. Eur Arch Otorhinolaryngol. 2015 Jan;272(1):185-93. doi: 10.1007/s00405-014-2973-y. Epub 2014 Mar 9.
72. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/ Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021 Aug;73(8):1366-83. doi: 10.1002/art.41773. Epub 2021 Jul 8.
73. Joshi L, Tanna A, McAdoo SP, et al. Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: Impact on localized and nonlocalized disease. Ophthalmology. 2015 Jun;122(6):1262-8. doi: 10.1016/j.ophtha.2015.01.016. Epub 2015 Mar 4.
74. Durel CA, Hot A, Trefond L, et al. Orbital mass in ANCA-associated vasculitides: Data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. Rheumatology (Oxford). 2019 Sep 1;58(9):1565-73. doi: 10.1093/rheumatology/kez071.
75. Holle JU, Gross WL, Holl-Ulrich K, et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis. 2010 Nov;69(11):1934-9. doi: 10.1136/ard.2010.130203.
76. Girard C, Charles P, Terrier B, et al. Tracheobronchial stenoses in granulomatosis with polyangi itis (Wegener’s): A report on 26 cases. Medicine (Baltimore). 2015 Aug;94(32): e1088. doi: 10.1097/MD.0000000000001088.
Рецензия
При поддержке: Статья подготовлена в рамках Государственного задания по теме №1021051402790-6. Исследование не имело спонсорской поддержки
Для цитирования:
Егорова О.Н., Харламова Е.Н., Тарасова Г.М. Дифференциальная диагностика локальной формы гранулематоза с полиангиитом: поражение органа зрения и органа слуха (часть 2). Современная ревматология. 2023;17(2):7-15. https://doi.org/10.14412/1996-7012-2023-2-7-15
For citation:
Egorova O.N., Kharlamova E.N., Tarasova G.M. Differential diagnosis of a local form of granulomatosis with polyangiitis: ocular and ear involvement (part 2). Modern Rheumatology Journal. 2023;17(2):7-15. (In Russ.) https://doi.org/10.14412/1996-7012-2023-2-7-15
Просмотров: 295
Послать статью по эл. почте 